JP2018512402A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512402A5
JP2018512402A5 JP2017548142A JP2017548142A JP2018512402A5 JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5 JP 2017548142 A JP2017548142 A JP 2017548142A JP 2017548142 A JP2017548142 A JP 2017548142A JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5
Authority
JP
Japan
Prior art keywords
immunoconjugate
immune complex
subject
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017548142A
Other languages
English (en)
Japanese (ja)
Other versions
JP6847846B2 (ja
JP2018512402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/022085 external-priority patent/WO2016145354A1/en
Publication of JP2018512402A publication Critical patent/JP2018512402A/ja
Publication of JP2018512402A5 publication Critical patent/JP2018512402A5/ja
Application granted granted Critical
Publication of JP6847846B2 publication Critical patent/JP6847846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017548142A 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略 Expired - Fee Related JP6847846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562132251P 2015-03-12 2015-03-12
US62/132,251 2015-03-12
US201562267386P 2015-12-15 2015-12-15
US62/267,386 2015-12-15
PCT/US2016/022085 WO2016145354A1 (en) 2015-03-12 2016-03-11 Dosing strategies for targeting epcam positive bladder cancer

Publications (3)

Publication Number Publication Date
JP2018512402A JP2018512402A (ja) 2018-05-17
JP2018512402A5 true JP2018512402A5 (enExample) 2019-04-18
JP6847846B2 JP6847846B2 (ja) 2021-03-24

Family

ID=56879327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548142A Expired - Fee Related JP6847846B2 (ja) 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略

Country Status (8)

Country Link
US (1) US10583198B2 (enExample)
EP (1) EP3268041A4 (enExample)
JP (1) JP6847846B2 (enExample)
CN (1) CN107580501A (enExample)
AU (1) AU2016228760B2 (enExample)
CA (1) CA2979400A1 (enExample)
HK (1) HK1249731A1 (enExample)
WO (1) WO2016145354A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
MX2016004239A (es) 2013-10-02 2016-11-14 Viventia Bio Inc Anticuerpos anti-epcam y métodos de uso.
WO2016145354A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
JP6824183B2 (ja) 2015-03-12 2021-02-03 セセン バイオ,インコーポレイテッド Epcam陽性膀胱癌の処置方法
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
WO2023222024A1 (en) * 2022-05-18 2023-11-23 Bj Bioscience Inc. Bispecific antibodies targeting epcam and cd3
CN115109164A (zh) * 2022-06-07 2022-09-27 博际生物医药科技(杭州)有限公司 靶向epcam和cd3的双特异性抗体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
JP4540856B2 (ja) 1999-04-09 2010-09-08 ウニヴェルジテート・チューリッヒ キメラ免疫グロブリンまたは免疫グロブリン断片の新規安定化方法、および安定化された抗EGP−2scFv断片
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PL205352B1 (pl) 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
JP2005507659A (ja) 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
PT2382990E (pt) 2003-04-30 2014-12-29 Univ Zuerich Método para tratamento do cancro usando uma imunotoxina
AU2005224942B2 (en) 2004-03-19 2011-08-11 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
PL1766017T3 (pl) 2004-06-10 2015-08-31 Viventia Bio Inc Przeciwciało specyficzne wobec nowotworu
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
EP2079840A4 (en) 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
US8318472B2 (en) 2007-09-27 2012-11-27 Viventia Biotechnologies Inc. Optimized nucleic acid sequences for the expression of VB4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CA2756246A1 (en) 2009-04-08 2010-10-14 Heinz Faulstich Amatoxin-armed target-binding moieties for the treatment of cancer
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
WO2014166002A1 (en) 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
MX2016004239A (es) 2013-10-02 2016-11-14 Viventia Bio Inc Anticuerpos anti-epcam y métodos de uso.
WO2016145354A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
JP6824183B2 (ja) 2015-03-12 2021-02-03 セセン バイオ,インコーポレイテッド Epcam陽性膀胱癌の処置方法
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2018512402A5 (enExample)
JP2016528247A5 (enExample)
JP2014158469A5 (enExample)
JP2018518454A5 (enExample)
JP2016520082A5 (enExample)
JP2017506217A5 (enExample)
JP2016094424A5 (enExample)
JP2019519499A5 (enExample)
RU2019106663A (ru) Комбинированная терапия рака
JP2020508317A5 (enExample)
JP2012501626A5 (enExample)
JP2013520442A5 (enExample)
JP2009533367A5 (enExample)
JP2018505177A5 (enExample)
JP2011506483A5 (enExample)
JP2015534579A5 (enExample)
JP2017501167A5 (enExample)
JP2016519650A5 (enExample)
SI2719708T1 (en) Material and methods for treating or preventing HER-3-related diseases
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2015517529A5 (enExample)
JP2020510039A5 (enExample)
JP2018529661A5 (enExample)
WO2016090024A4 (en) Combination therapy for treatment of cancer